ES2242448T3 - Metodos y composiciones para el tratamiento de trastornos proliferativos celulares. - Google Patents

Metodos y composiciones para el tratamiento de trastornos proliferativos celulares.

Info

Publication number
ES2242448T3
ES2242448T3 ES99968523T ES99968523T ES2242448T3 ES 2242448 T3 ES2242448 T3 ES 2242448T3 ES 99968523 T ES99968523 T ES 99968523T ES 99968523 T ES99968523 T ES 99968523T ES 2242448 T3 ES2242448 T3 ES 2242448T3
Authority
ES
Spain
Prior art keywords
glcnac
composition
approximately
poly
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99968523T
Other languages
English (en)
Spanish (es)
Inventor
John N. Vournakis
Sergio Finkielsztein
Ernest R. Pariser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Application granted granted Critical
Publication of ES2242448T3 publication Critical patent/ES2242448T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
ES99968523T 1998-12-22 1999-12-21 Metodos y composiciones para el tratamiento de trastornos proliferativos celulares. Expired - Lifetime ES2242448T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/218,288 US6063911A (en) 1993-12-01 1998-12-22 Methods and compositions for treatment of cell proliferative disorders
US218288 2002-08-14

Publications (1)

Publication Number Publication Date
ES2242448T3 true ES2242448T3 (es) 2005-11-01

Family

ID=22814511

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99968523T Expired - Lifetime ES2242448T3 (es) 1998-12-22 1999-12-21 Metodos y composiciones para el tratamiento de trastornos proliferativos celulares.

Country Status (14)

Country Link
US (1) US6063911A (https=)
EP (1) EP1139752B1 (https=)
JP (1) JP4795539B2 (https=)
CN (1) CN100488512C (https=)
AT (1) ATE294504T1 (https=)
AU (1) AU780248B2 (https=)
CA (1) CA2356087C (https=)
DE (1) DE69925156T2 (https=)
ES (1) ES2242448T3 (https=)
HK (1) HK1043507B (https=)
IL (2) IL143700A0 (https=)
NO (1) NO330033B1 (https=)
NZ (1) NZ512586A (https=)
WO (1) WO2000036918A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US7566452B1 (en) * 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
MXPA02006461A (es) 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
HRP20030124A2 (en) * 2000-08-22 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
US7041657B2 (en) * 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
WO2004060172A1 (en) 2002-12-31 2004-07-22 Marine Polymer Technologies, Inc. Hemostatic compositions and uses therefor
JP2006516571A (ja) * 2003-01-17 2006-07-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 良性前立腺増殖症の処置
JP5028086B2 (ja) * 2003-02-24 2012-09-19 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞−ポリマー繊維組成物及びその使用
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
NZ546204A (en) 2003-09-12 2009-12-24 Marinepolymer Tech Inc Vascular access preservation in haemodialysis patients
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US20080166323A1 (en) * 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
AU2008219065B2 (en) * 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
NZ599338A (en) * 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
ES2598005T3 (es) 2009-08-14 2017-01-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
GB201616087D0 (en) * 2016-09-21 2016-11-02 Tomalgae Cvba Algae comprising therapeutic and/or nutritional agents
US12239720B2 (en) 2018-04-06 2025-03-04 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) * 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3989535A (en) * 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US3988411A (en) * 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
JPS55152705A (en) * 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
US4378017A (en) * 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
US4803168A (en) * 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
IL80032A (en) * 1985-09-23 1992-07-15 Lilly Co Eli Anti-tumor phenyl-aminocarbonylsulfonamides,their preparation and pharmaceutical compositions containing them
JPS62288602A (ja) * 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5071977A (en) * 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
US5116747A (en) * 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5219749A (en) * 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
HUT67665A (en) * 1991-11-05 1995-04-28 Smithkline Beckman Corp Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
IL100096A (en) * 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5624679A (en) * 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (https=) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1996039122A1 (en) * 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
US5998468A (en) * 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
WO1997037987A1 (en) * 1996-04-10 1997-10-16 Warner-Lambert Company Ketoacid endothelin antagonists

Also Published As

Publication number Publication date
ATE294504T1 (de) 2005-05-15
AU780248B2 (en) 2005-03-10
NZ512586A (en) 2004-01-30
AU2591900A (en) 2000-07-12
HK1043507B (zh) 2009-12-24
NO20013071L (no) 2001-08-20
NO20013071D0 (no) 2001-06-20
DE69925156T2 (de) 2006-02-16
WO2000036918A1 (en) 2000-06-29
CN1335749A (zh) 2002-02-13
US6063911A (en) 2000-05-16
JP4795539B2 (ja) 2011-10-19
EP1139752A1 (en) 2001-10-10
DE69925156D1 (de) 2005-06-09
CA2356087C (en) 2009-02-17
CA2356087A1 (en) 2000-06-29
IL143700A0 (en) 2002-04-21
NO330033B1 (no) 2011-02-07
IL143700A (en) 2006-08-01
EP1139752A4 (en) 2003-01-02
EP1139752B1 (en) 2005-05-04
WO2000036918A9 (en) 2000-11-23
JP2003522732A (ja) 2003-07-29
CN100488512C (zh) 2009-05-20
HK1043507A1 (zh) 2002-09-20

Similar Documents

Publication Publication Date Title
ES2242448T3 (es) Metodos y composiciones para el tratamiento de trastornos proliferativos celulares.
ES2607802T3 (es) Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia
US6610668B2 (en) Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
Bashir et al. N-succinyl chitosan preparation, characterization, properties and biomedical applications: a state of the art review
ES2477316T3 (es) Composiciones y métodos para la modulación de la estructura y/o función vascular
CN101808668B (zh) 药物内包活性靶向型高分子微团、医药组合物
CA2145502A1 (en) Alginate-bioactive agent conjugates
ES2698123T3 (es) Polímero anfifílico basado en ácido hialurónico, método de preparación y su aplicación
US20090247738A1 (en) Biocompatible poly-beta-1-4-n-acetylglucosamine
EP0640622A1 (en) Polysaccharide derivative and drug carrier
MXPA01004239A (es) Compuesto dds y metodo para la medicion del mismo.
ES2366841B1 (es) Nanoparticulas de silice para difusion intracelular de agentes bioactivos poco solubles
WO2014041231A1 (es) Hidrogel útil como soporte inyectable para aplicación en terapia celular y como sistema de liberación controlada de fármacos
ES2874075T3 (es) Nuevos hidrogeles de estructura sililada y procedimiento de obtención
AU2009209541A1 (en) Improved antitumoral treatments
WO2013127885A1 (en) A conjugate of methotrexate and hydroxyethyl starch for use in the treatment cancer
Chen et al. Enzyme-instructed self-assembly of peptides: Process, dynamics, nanostructures, and biomedical applications
MXPA01006483A (en) Methods and compositions for treatment of cell proliferative disorders
Musale et al. CHITOSAN AND THIOLATED CHITOSAN DERIVATIVES: A BRIEF
CN106620663A (zh) 糖‑血红蛋白纳米粒子的制备方法及用途
渡辺邦人 et al. 6-O-carboxymethyl-chitin (CM-chitin) as a drug carrier.
JPWO2000025825A1 (ja) Ｄｄｓ化合物及びその測定方法